| Literature DB >> 34794122 |
William J Gradishar1, Meena S Moran2, Jame Abraham3, Rebecca Aft4, Doreen Agnese5, Kimberly H Allison6, Sarah L Blair7, Harold J Burstein8, Chau Dang9, Anthony D Elias10, Sharon H Giordano11, Matthew P Goetz12, Lori J Goldstein13, Sara A Hurvitz14, Steven J Isakoff15, Rachel C Jankowitz16, Sara H Javid17, Jairam Krishnamurthy18, Marilyn Leitch19, Janice Lyons3, Jennifer Matro16, Ingrid A Mayer20, Joanne Mortimer21, Ruth M O'Regan22, Sameer A Patel13, Lori J Pierce23, Hope S Rugo24, Amy Sitapati7, Karen Lisa Smith25, Mary Lou Smith26, Hatem Soliman27, Erica M Stringer-Reasor28, Melinda L Telli6, John H Ward29, Kari B Wisinski22, Jessica S Young30, Jennifer L Burns31, Rashmi Kumar31.
Abstract
The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.Entities:
Mesh：
Year: 2021 PMID： 34794122 DOI： 10.6004/jnccn.2021.0023
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908